Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

iBio (IBIO) Total Current Liabilities (2016 - 2025)

iBio (IBIO) has disclosed Total Current Liabilities for 15 consecutive years, with $5.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Total Current Liabilities rose 25.31% to $5.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $5.9 million, a 25.31% increase, with the full-year FY2025 number at $6.1 million, up 59.01% from a year prior.
  • Total Current Liabilities was $5.9 million for Q4 2025 at iBio, down from $6.0 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $32.2 million in Q3 2022 to a low of $3.5 million in Q3 2024.
  • A 5-year average of $13.6 million and a median of $8.2 million in 2021 define the central range for Total Current Liabilities.
  • Peak YoY movement for Total Current Liabilities: soared 358.03% in 2022, then crashed 83.25% in 2024.
  • iBio's Total Current Liabilities stood at $8.3 million in 2021, then surged by 232.79% to $27.8 million in 2022, then fell by 22.4% to $21.6 million in 2023, then tumbled by 78.15% to $4.7 million in 2024, then rose by 25.31% to $5.9 million in 2025.
  • Per Business Quant, the three most recent readings for IBIO's Total Current Liabilities are $5.9 million (Q4 2025), $6.0 million (Q3 2025), and $6.1 million (Q2 2025).